Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sunovion
• Treatments: Eszopiclone

Criteria

Inclusion Criteria:

Inclusion Criteria:

• Subject is male or female 6 17 years of age, inclusive, at the time of consent.

• Subject must have a diagnosis of ADHD as defined by DSM-IV criteria • The diagnosis for Rollover subjects will be taken from the Screening visit of Study 190 246. Treatment naïve subjects will have these assessments performed at the Screening visit.

• Subject must have documented ADHD associated insomnia, defined as the subject or subject's parent/legal guardian having reported repeated difficulty with sleep initiation (sleep latency >30 minutes) or consolidation (wake time after sleep onset > 45 minutes),>despite adequate age appropriate time and opportunity for sleep.

• Subject has either >30 minutes latency to persistent sleep (LPS) or >45 minutes wake time after sleep onset (WASO) demonstrated by PSG.

• Subject or subject's parent/legal guardian should have reported daytime functional impairment as a result of sleep problems.

• Subject or subject's parent/legal guardian should have reported attempted and failed behavioral interventions for sleep problems, including a regular bedtime and rise time.

• Subject's sleep disturbance must not be attributable to either the direct physiologic effect of a drug of abuse or misuse of a prescribed medication whether it is being used as intended or in an illicit manner.

• Female subjects ≥8 years of age must have a negative serum pregnancy test at screening

• Subject must be in good general health.

• Subject must be able to swallow tablets.

• If subjects are currently taking medication for ADHD, they must be on a stable dose and regimen for at least one month, and preferably for at least 3 months prior to the time of consent

Exclusion Criteria:

• Subject with weight <10th percentile for age and gender

• Subject has any clinically significant or unstable medical abnormality/illness

• Subject has a documented history of Bipolar I or II Disorder, major depression, conduct disorder, generalized anxiety disorder (other than obsessive-compulsive disorder) or any history of psychosis, as determined by medical or psychiatric history or as determined by clinical interview using the MINI-Kid at Visit 1.

• Subject has periodic limb movement >5 times per hour, as demonstrated on PSG.

• Subject has sleep disordered breathing, as demonstrated on PSG.

• Subject has another primary sleep disorder (or secondary sleep disorder that is causing clinical impairment or any other known or suspected medical or psychiatric condition that has affected or may affect sleep

• Subject has a history of circadian rhythm disorder or will travel across ≥3 time zones more than once during the study.

• Subject has organic brain disease, or a history of febrile seizures.

• Subject is, in the opinion of the investigator, at suicidal or homicidal risk.

• Female subject who is pregnant, lactating or planning to become pregnant.

• Subject is taking any psychotropic or disallowed medications,

• Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.

• Subject has a history of allergic reaction or has a known or suspected sensitivity to racemic zopiclone, eszopiclone, or any substance that is contained in the formulation.

• Subject has a history of alcohol or substance abuse within 3 months of study participation

• Subject has participated in any investigational study within 30 days prior to study entry or is currently participating in another clinical trial, except Study 190 246.